Recent Advances and New Perspectives in Managing Macular Degeneration [Working Title]最新文献

筛选
英文 中文
OCT Biomarkers for AMD AMD的OCT生物标志物
Luciana de Sá Quirino-Makarczyk, Maria de Fátima Sainz Ugarte
{"title":"OCT Biomarkers for AMD","authors":"Luciana de Sá Quirino-Makarczyk, Maria de Fátima Sainz Ugarte","doi":"10.5772/INTECHOPEN.97752","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.97752","url":null,"abstract":"Age-related Macular Degeneration (AMD) is an acquired retina disease that can potentially cause significant central visual impairment. Optical coherence tomography (OCT) applied to the study of retinal pathologies has revolutionized the understanding and management of AMD, especially with the technology of full-depth imaging (FDI) Spectral Domain (SD) OCT. With the increasing amount of data from several important studies using SD-OCT and OCT-angiography (OCT-A) we can now better classify and more accurately decode AMD. The purpose of this chapter is to describe the most important AMD biomarkers recently discovered using SD OCT. Understanding AMD phenotype is very important to define prognosis and individualized forms of treatment and follow up. Biomarkers on OCT have been crucial for a better understanding of AMD.","PeriodicalId":141797,"journal":{"name":"Recent Advances and New Perspectives in Managing Macular Degeneration [Working Title]","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115608316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-VEGF Treatment and Optical Coherence Tomography Biomarkers in Wet Age-Related Macular Degeneration 湿性年龄相关性黄斑变性的抗vegf治疗和光学相干断层扫描生物标志物
M. Vinković, Andrijana Kopić, Tvrtka Benašić
{"title":"Anti-VEGF Treatment and Optical Coherence Tomography Biomarkers in Wet Age-Related Macular Degeneration","authors":"M. Vinković, Andrijana Kopić, Tvrtka Benašić","doi":"10.5772/INTECHOPEN.97689","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.97689","url":null,"abstract":"Age-related macular degeneration (AMD) is one of the most common causes of severe visual loss in middle and old-age population, and often leads to serious deterioration in quality of life. Currently, the first-line treatment for neovascular AMD (nAMD) are intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications, including bevacizumab, ranibizumab, and aflibercept and also latest commercially available drug, brolucizumab. During initial examination and imaging and treatment follow-up for patients with nAMD, optical coherence tomography (OCT) is used to predict and assess the therapeutic response and guide the treatment. Several OCT-based biomarkers, including the central subfoveal thickness (CSFT), the presence of intraretinal cysts (IRCs) or subretinal fluid (SRF), and the presence of pigment epithelial detachment (PED), were found to influence baseline visual acuity or visual improvements. Recent analyses of large randomized control trials (RCTs) summarized the usefulness of these OCT-based biomarkers. However, many of these early studies relied on time-domain OCT to evaluate the retinal structures thus providing less precise evaluation of the retinal details. After introduction of spectral-domain OCT (SD-OCT) which provided high resolution images, recent studies offered new insights in specific morphological changes and their different impact on visual function in nAMD. For example, these advancement in resolution offered new classification of IRCs into degenerative and exudative which impacts treatment strategy and final outcome in the treatment of nAMD. Moreover, the recent data disclose a substantial difference between RCTs and real-world studies regarding the response to anti-VEGF therapy. In conclusions, IRCs and PED are associated with poor visual improvement in nAMD in a realworld setting. Both IRCs and SRF responded better than PED to anti-VEGF therapy. These observations mandate large longitudinal studies focusing on the usefulness of these high resolution SD-OCT biomarkers in real-world situations.","PeriodicalId":141797,"journal":{"name":"Recent Advances and New Perspectives in Managing Macular Degeneration [Working Title]","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124319111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Drugs in the Pipeline for the Management of AMD 用于治疗AMD的新药正在研发中
A. Marta, B. Pessoa
{"title":"New Drugs in the Pipeline for the Management of AMD","authors":"A. Marta, B. Pessoa","doi":"10.5772/INTECHOPEN.97665","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.97665","url":null,"abstract":"Anti-vascular endothelial growth factor (anti-VEGF) therapies have revolutionized the care of patients with retinal diseases. In the 1990s, it was observed that anti-VEGF antibodies reduced tumor angiogenesis, and consequently, these antibodies started to be used off-label in the exudative form of age-related macular degeneration (AMD). In the 2000s, research was directed towards the development of anti-VEGF therapies for retinal disease management. Several anti-VEGF therapies were approved: pegaptanib, an RNA aptamer, in 2004; ranibizumab, an anti-VEGF Fab, in 2008; aflibercept, a humanized IgG Fc, in 2011; and brolucizumab, an scFv, in 2019. Currently, new therapeutic options are emerging, and approval is expected soon. These new therapies aim to increase treatment durability and thus reduce treatment burden and improve real-world outcomes. In this chapter, the mechanisms of action and the preliminary trial results of these potential new therapies will be described.","PeriodicalId":141797,"journal":{"name":"Recent Advances and New Perspectives in Managing Macular Degeneration [Working Title]","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127941887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书